23.43
-4.62(-16.47%)
Currency In USD
| Previous Close | 28.05 |
| Open | 25.35 |
| Day High | 26.49 |
| Day Low | 23.27 |
| 52-Week High | 50.4 |
| 52-Week Low | 16.54 |
| Volume | 1.7M |
| Average Volume | 956,585.1 |
| Market Cap | 668.27M |
| PE | -14.37 |
| EPS | -1.63 |
| Moving Average 50 Days | 39.32 |
| Moving Average 200 Days | 30.95 |
| Change | -4.62 |
If you invested $1000 in LENZ Therapeutics, Inc. (LENZ) since IPO date, it would be worth $1,446.3 as of November 05, 2025 at a share price of $23.43. Whereas If you bought $1000 worth of LENZ Therapeutics, Inc. (LENZ) shares 6 months ago, it would be worth $805.15 as of November 05, 2025 at a share price of $23.43.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025
GlobeNewswire Inc.
Oct 29, 2025 12:00 PM GMT
SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-ap
LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States
GlobeNewswire Inc.
Sep 30, 2025 12:00 PM GMT
VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is the first and only aceclidine-based eye drop approved
LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences
GlobeNewswire Inc.
Aug 25, 2025 12:00 PM GMT
SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-ap